Condition: Pancreatic Adenocarcinoma · Homologous Recombination Deficiency · Sponsor: Fudan University
The purpose of this study is to evaluate the efficacy of cisplatin based regimen to patients with advanced pancreatic cancer and homologous recombination deficiency.
This description comes directly from the study's public registry record.
Ying Yang, MD · 86 64175590 · yangying@fudanpci.org
Always discuss trial participation with your own doctor first.
| Shanghai Cancer Center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06095141